Abstract
Tuberculosis (TB) is an infectious disease caused mainly by members of Mycobacterium tuberculosis complex. In 2012, the WHO estimated 8.7 million new cases and 1.4 million deaths caused by this disease. Under the Millennium Development Goals, the WHO aims to eradicate TB as a public health problem by 2050. However, reaching this goal will require the development and incorporation of new and more effective vaccines that can replace the current BCG vaccine. Much work is therefore ongoing in terms of the development of TB vaccines and more than 10 candidate vaccines are progressing well through the different development stages. The aim of this mini-review is to describe the characteristics of the most promising vaccines, and to give a brief description of some key elements relating to the current and future development of vaccines against TB.
Keywords: BCG, Development, Tuberculosis, Vaccine.
Current Pharmaceutical Biotechnology
Title:Update on the Development of TB Vaccines
Volume: 14 Issue: 11
Author(s): Roberto Zenteno-Cuevas
Affiliation:
Keywords: BCG, Development, Tuberculosis, Vaccine.
Abstract: Tuberculosis (TB) is an infectious disease caused mainly by members of Mycobacterium tuberculosis complex. In 2012, the WHO estimated 8.7 million new cases and 1.4 million deaths caused by this disease. Under the Millennium Development Goals, the WHO aims to eradicate TB as a public health problem by 2050. However, reaching this goal will require the development and incorporation of new and more effective vaccines that can replace the current BCG vaccine. Much work is therefore ongoing in terms of the development of TB vaccines and more than 10 candidate vaccines are progressing well through the different development stages. The aim of this mini-review is to describe the characteristics of the most promising vaccines, and to give a brief description of some key elements relating to the current and future development of vaccines against TB.
Export Options
About this article
Cite this article as:
Zenteno-Cuevas Roberto, Update on the Development of TB Vaccines, Current Pharmaceutical Biotechnology 2013; 14 (11) . https://dx.doi.org/10.2174/1389201014666131226124940
DOI https://dx.doi.org/10.2174/1389201014666131226124940 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The role of interleukin 35 in atherosclerosis
Current Pharmaceutical Design Polyphenol Supplementation as a Complementary Medicinal Approach to Treating Inflammatory Bowel Disease
Current Medicinal Chemistry Distinction Between Esterases and Lipases: Comparative Biochemical Properties of Sequence-Related Carboxylesterases
Protein & Peptide Letters Natural Aristolochia Alkaloid Aristololactam-β-D-glucoside: Interaction with Biomacromolecules and Correlation to the Biological Perspectives
Mini-Reviews in Medicinal Chemistry The Application of High Throughput siRNA Screening Technology to Study Host-Pathogen Interactions
Combinatorial Chemistry & High Throughput Screening Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Polypharmacology in Drug Discovery)
Current Pharmaceutical Design Interethnic and Intraethnic Variability of NAT2 Single Nucleotide Polymorphisms
Current Drug Metabolism Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry Mass Spectrometry-Based Proteomics and its Application to Studies of Porphyromonas gingivalis Invasion and Pathogenicity
Infectious Disorders - Drug Targets Novel Applications of Nanotechnology in Controlling HIV and HSV Infections
Current Drug Research Reviews Pyrimidine Salvage Pathway in Mycobacterium tuberculosis
Current Medicinal Chemistry Functional Consequences of Immune Cell Adhesion to Endothelial Cells
Current Pharmaceutical Design Adenylating Enzymes in Mycobacterium tuberculosis as Drug Targets
Current Topics in Medicinal Chemistry Mechanism of Actions of Non Peptide Antigens Activating Human Vγ9 / Vδ2 T Lymphocytes and their Potential Use for Immunointervention
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Enoyl Reductases as Targets for the Development of Anti-Tubercular and Anti-Malarial Agents
Current Drug Targets Innate Immunity, Toll-Like Receptors, and Diabetes
Current Immunology Reviews (Discontinued)